Spotlight on Myeloma 2024: Innovations and Insights from ASH
Stay up-to-date with the latest advancements in multiple myeloma treatment. Discover the benefits of integrating CD38 monoclonal antibodies and quadruplet regimens.
Stay up-to-date with the latest advancements in multiple myeloma treatment. Discover the benefits of integrating CD38 monoclonal antibodies and quadruplet regimens.
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
An abstract is unavailable.
After noticing a lump on the right side of his neck, Chu Nguyen, Ph.D., came to MD Anderson for a second opinion. Further testing revealed…
The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized …
An abstract is unavailable.
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.